EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications

Gilad Vainer iD, Lingkang Huang, Kenneth Emancipator, Shanthy Nuti

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0285764 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Gilad Vainer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Triple Negative Breast Neoplasms, Esophageal Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We conducted an analysis across multiple PD-L1 combined positive score (CPS) indications to establish concordance of a 22C3 antibody–based laboratory-developed test (LDT) on the Ventana BenchMark XT or BenchMark ULTRA platform and the regulatory-approved PD-L1 IHC 22C3 pharmDx in cervical cancer (CC), esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), and urothelial carcinoma (UC). Tumor specimens from each tumor type were stained with 22C3 antibody and scored using the 22C3 antibody–based LDT, and scores were compared with those using PD-L1 IHC 22C3 pharmDx. PD-L1 status was measured by the pathologist using CPS as a continuous score and using clinically relevant cutoffs (CC, ≥1 and ≥10; HNSCC, ≥1 and ≥20; ESCC, TNBC, and UC, ≥10). The agreement between the BenchMark platforms and PD-L1 IHC 22C3 pharmDx was assessed by intraclass correlation coefficient (ICC) and a contingency table for clinical interpretation. A total of 522 samples were evaluated for the pan-tumor analysis (CC, n = 77; ESCC, n = 80; HNSCC, n = 126; TNBC, n = 118, UC, n = 121). Most clinical interpretations of PD-L1 status were concordant between the BenchMark XT and PD-L1 IHC 22C3 pharmDx for all five tumor types with regard to negative percentage agreement (NPA; 83–97%), positive percentage agreement (PPA; 86–100%), and overall percentage agreement (OPA; 90–97%); the ICC by tumor type was high (≥0.88). Importantly, the pan-tumor ICC was 0.95 (95% CI 0.94–0.96). Thirty additional TNBC samples were evaluated using the BenchMark ULTRA and PD-L1 IHC 22C3 pharmDx; the NPA, PPA, and OPA were 100%. The 22C3 antibody–based LDT on Ventana BenchMark XT and BenchMark ULTRA platforms demonstrated high concordance with the regulatory-approved PD-L1 IHC 22C3 pharmDx across multiple tumor types. These findings suggest the comparability of PD-L1 IHC 22C3 pharmDx with an LDT based on the 22C3 antibody.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Transitional CellUrinary Bladder NeoplasmsTriple Negative Breast NeoplasmsEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaUterine Cervical NeoplasmsHead and Neck NeoplasmsLung NeoplasmsFemaleHumansImmunohistochemistrySquamous Cell Carcinoma of Head and NeckB7-H1 AntigenBiomarkers, TumorAntibodies

Substanzen

B7-H1 AntigenBiomarkers, TumorAntibodies

Autor:innen und Institutionen

  • Department of Pathology, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Department of Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, New Jersey, United States of America.
  • Department of Translational Medicine, Merck & Co., Inc., Rahway, New Jersey, United States of America.
  • Biomarkers and Diagnostics, Oncology, Global Medical and Scientific Affairs, MRL, Merck & Co., Inc., Rahway, New Jersey, United States of America.

ORCID-Profile: Gilad Vainer

Förderung

  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ.

Zitieren

APA

Vainer, G., Huang, L., Emancipator, K., & Nuti, S. (2023). Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications. PLOS ONE. https://doi.org/10.1371/journal.pone.0285764

Vancouver

Vainer G, Huang L, Emancipator K, Nuti S. Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications. PLOS ONE. 2023. doi:10.1371/journal.pone.0285764

BibTeX
@article{Vainer2023,
  author = {Vainer, Gilad and Huang, Lingkang and Emancipator, Kenneth and Nuti, Shanthy},
  title = {Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0285764}
}
Kostenlos starten →